Pharmaceuticals

Postherpetic Neuralgia Market 2026 witnessing steady demand growth

March 24, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Postherpetic Neuralgia (PHN) Market Over The Period 2026–2030?

The postherpetic neuralgia (phn) market has experienced robust expansion over recent years. Forecasts indicate it will expand from $0.77 billion in 2025 to reach $0.82 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this expansion has been driven by factors such as a rising occurrence of herpes zoster infections, insufficient therapeutic choices for neuropathic pain, dependence on opioid-centric pain management, an expanding older demographic, and the progressive broadening of hospital pain management services.

The postherpetic neuralgia (phn) market is poised for significant expansion in the coming years, with projections indicating a rise to $1.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is largely driven by the development of targeted neuropathic pain therapies, increased adoption of biologic and branded drugs, the proliferation of online pharmacy distribution channels, a heightened focus on patient-centric pain management approaches, and the expansion of outpatient and ambulatory care facilities. Furthermore, major trends anticipated in this period include the rising prevalence of shingles within the aging population, a growing preference for non-opioid pain management therapies, the increasing utilization of transdermal and topical pain relief solutions, a greater demand for long-term chronic pain management strategies, and improved awareness coupled with earlier diagnosis of phn.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Underlying Factors Are Accelerating The Growth Of The Postherpetic Neuralgia (PHN) Market?

The escalating occurrence of chronic pain conditions is projected to fuel the expansion of the postherpetic neuralgia (PHN) market in the foreseeable future. Chronic pain is defined as pain that persists or recurs for over 3 months, frequently extending beyond the typical duration of an illness or injury and negatively impacting an individual’s daily activities and overall well-being. The widespread presence of chronic pain conditions stems from the aging demographic, given that elderly individuals are more susceptible to degenerative ailments such as arthritis and neuropathy, which result in ongoing pain. Postherpetic neuralgia serves as a valuable area for chronic pain research because it offers a distinct model for investigating nerve-related pain processes and assessing extended treatment approaches. For example, a report released in January 2024 by the Office for Health Improvement and Disparities, a UK government body, indicated that approximately 18.4% of individuals aged 16 and above reported experiencing a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Consequently, the rising occurrence of chronic pain conditions is a significant factor propelling the expansion of the postherpetic neuralgia (PHN) market.

How Is The Postherpetic Neuralgia (PHN) Market Divided Into Its Major Segments?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

How Are Trends Transforming The Postherpetic Neuralgia (PHN) Market Landscape?

Major companies in the postherpetic neuralgia (PHN) market are concentrating on obtaining regulatory clearances to expand their product lines, gain a competitive edge, and address the considerable unmet clinical need for more effective and tolerable treatments. Regulatory approvals refer to the official authorizations issued by government health authorities that allow a drug or therapy to be legally sold and used for a specific medical condition. For example, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, secured final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for managing postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, which is a type of neuropathic pain arising from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing starts at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as needed for pain relief.

Who Are The Prominent Organizations Shaping The Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Read the full postherpetic neuralgia (phn) market report here:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Is Projected To Dominate The Postherpetic Neuralgia (PHN) Market During The Forecast Period?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Postherpetic Neuralgia (PHN) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795